Capricor Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Capricor Therapeutics Inc in the first quarter 2026?
Capricor Therapeutics Inc recorded a cumulative net loss of $-115 million during 12 months ending in the first quarter 2026, resulting in a negative return on equity (ROE) of -59.27%.

Within the Major Pharmaceutical Preparations industry 177 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 2724, from total ROE ranking in the fourth quarter 2025 at 3017.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Equity Change	118.34 %	110.22 %	22.86 %	812.66 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-115	-105	-82	-70	-55
Return On Equity (TTM)	-59.27 %	-67.52 %	-70.99 %	-62.71 %	-62.42 %
CAPR's Total Ranking	# 2724	# 3017	# 2100	# 2826	# 3039
Equity (TTM) in Millions	279	306	84	105	128
Seq. Equity Change	-8.86 %	264.61 %	-20.11 %	-17.76 %	-12.25 %
Seq. Net Income Change	-	-	-	-	-

Back to CAPR Management Effectiveness >> CAPR's 5 Years Annual ROE >> Compare CAPR ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 178
Sector	# 413
Overall	# 2724

Return On Equity Statistics
High	Average	Low
89.01 %	-147.48 %	-617.8 %
(Mar 31 2018)		(Sep 30 2023)

CAPR Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	306	145	23	12	31
Y / Y Equity Change	110.22 %	543.6 %	91.76 %	-62.43 %	11.23 %
Net Income in Millions	-105	-40	-22	-29	-20
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-34.35 %	-27.82 %	-98.61 %	-246.22 %	-63.83 %

Back to CAPR Management Effectiveness >> CAPR's 5 Years Annual ROE >> Compare CAPR ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CAPR's' Return on Equity at Yahoo Finance
CAPR's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CAPR's Competitors
Subscribers only: Roe for Capricor Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for CAPR's Customers

Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector

ROE

Date modified: 2026-08-30T14:47:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.